Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug

Published on January 3, 2022

Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.

Continue reading on website
Other news

United Airlines (UAL) Offers Staff Higher Pay Through January

January 3, 2022
United Airlines (UAL) offers its pilots and flight attendants higher pay through January to encourage them to pick up more flying as it grapples with staffing shortages amid a spike...

Does Mastercard Stock Deserve a Place in Your Portfolio?

January 3, 2022
Leading transaction processing company Mastercard (MA) has benefited from the increased online transactions over the past 18 months. However, the rising popularity of alternative platforms such as Venmo and Paypal...